MX2007003910A - T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents. - Google Patents

T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.

Info

Publication number
MX2007003910A
MX2007003910A MX2007003910A MX2007003910A MX2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A
Authority
MX
Mexico
Prior art keywords
tcr
cell receptors
terminus
amino acid
acid sequence
Prior art date
Application number
MX2007003910A
Other languages
Spanish (es)
Inventor
Bent Karsten Jakobsen
Torben Bent Andersen
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0421836.8A external-priority patent/GB0421836D0/en
Priority claimed from GB0427584A external-priority patent/GB0427584D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of MX2007003910A publication Critical patent/MX2007003910A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention provides a dimeric TCR (dTCR) or single-chain TCR (scTCR) associated with selected therapeutic agents, wherein said TCR comprises a first segment constituted by an amino acid sequence corresponding to a TCR chain variable domain sequence fused to the N terminus of an amino acid sequence corresponding to a TCR chain constant domain extracellular sequence, a second segment constituted by an amino acid sequence corresponding to a TCR a chain variable domain fused to the N terminus of an amino acid sequence corresponding to TCR a chain constant domain extracellular sequence, a disulfide bond between the first and second chains, said disulfide bond being one which has no equivalent in native a T cell receptors, and in the case of said scTCRs further comprising a linker sequence linking the C terminus of the first segment to the N terminus of the second segment, or vice versa, the length of the linker sequence and the position of the disulfide bond being suc h that the variable domain sequences of the first and second segments are mutually orientated substantially as in native a T cell receptors.
MX2007003910A 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents. MX2007003910A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0421836.8A GB0421836D0 (en) 2004-10-01 2004-10-01 T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents
US62106304P 2004-10-25 2004-10-25
GB0427584A GB0427584D0 (en) 2004-12-16 2004-12-16 T cell receptors containing a novel disulfide interchain bond linked to immunomodulatory agents
PCT/GB2005/003752 WO2006037960A2 (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents

Publications (1)

Publication Number Publication Date
MX2007003910A true MX2007003910A (en) 2007-06-07

Family

ID=36000822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003910A MX2007003910A (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.

Country Status (6)

Country Link
EP (1) EP1809669A2 (en)
JP (1) JP2008514685A (en)
AU (1) AU2005291039A1 (en)
CA (1) CA2582963A1 (en)
MX (1) MX2007003910A (en)
WO (1) WO2006037960A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130105885A (en) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
DK2158220T3 (en) 2007-06-26 2017-07-10 F-Star Biotechnologische Forschungs- Und Entw M B H Display of binders
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102161998B (en) 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof
MX2013014388A (en) * 2011-06-09 2014-08-21 Health Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes.
EP2755993B1 (en) 2011-09-16 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Pseudomonas exotoxin a with less immunogenic b cell epitopes
EP2760892A1 (en) * 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CN103130894B (en) * 2011-11-30 2017-04-12 中国医学科学院基础医学研究所 Recombinant single-chain antibody G5-4ScFv of anti-human gamma delta T cell receptor (TCR) monoclonal antibody and encoding gene and application thereof
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
CN105683215B (en) 2013-06-26 2021-04-23 香雪生命科学技术（广东）有限公司 High-stability T cell receptor and preparation method and application thereof
EP3216801B1 (en) * 2014-11-07 2020-01-01 Guangdong Xiangxue Life Sciences, Ltd. Soluble heterodimeric t cell receptor, and preparation method and use thereof
CN106279404A (en) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 A kind of solvable and stable heterogeneous dimerization TCR
IL262772B2 (en) 2016-05-06 2023-10-01 Juno Therapeutics Inc Genetically engineered cells and methods of making the same
JP2019517499A (en) 2016-06-02 2019-06-24 イムノコア リミテッド Dosage regimen of gp100-specific TCR-anti-CD3 scFv fusion protein
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
CN110291402B (en) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 Method for identifying peptide epitopes, molecules binding such epitopes and related uses
CN110139873A (en) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 HPV specific binding molecules
EP3548055A4 (en) * 2016-12-02 2020-08-19 University of Southern California Synthetic immune receptors and methods of use thereof
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MX2019009848A (en) 2017-02-20 2019-12-19 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16.
MX2020003536A (en) 2017-10-03 2020-09-14 Juno Therapeutics Inc Hpv-specific binding molecules.
BR112020008478A2 (en) 2017-11-01 2020-10-20 Editas Medicine, Inc. methods, compositions and components for editing crispr-cas9 of tgfbr2 in t cells for immunota-rapy
JP2021502077A (en) 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
CN112368012A (en) 2018-02-08 2021-02-12 蜻蜓疗法股份有限公司 Antibody variable domains targeting NKG2D receptor
SG11202009284TA (en) 2018-04-05 2020-10-29 Juno Therapeutics Inc T cell receptors and engineered cells expressing same
KR20210029707A (en) 2018-04-05 2021-03-16 주노 쎄러퓨티크스 인코퍼레이티드 Method for producing cells expressing recombinant receptors and related compositions
CA3095084A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
EA202091977A1 (en) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
KR20210057730A (en) 2018-08-09 2021-05-21 주노 쎄러퓨티크스 인코퍼레이티드 Engineered cells and methods of producing compositions
US20220050114A1 (en) 2018-09-11 2022-02-17 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
KR20220016475A (en) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 Cells, Associated Polynucleotides and Methods Expressing Recombinant Receptors at the Modified TFTFR2 Locus
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AU2021244937A1 (en) 2020-03-27 2022-11-03 Mendus B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023531531A (en) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
EP4240405A1 (en) 2020-11-05 2023-09-13 Mendus B.V. Use of tumor-independent antigens in immunotherapies
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CN116496408A (en) * 2022-01-21 2023-07-28 广东菲鹏制药股份有限公司 Interleukin 21 and receptor complexes thereof
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001974A (en) * 2001-08-31 2004-07-16 Avidex Ltd Soluble t cell receptor.
NZ539225A (en) * 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
DK1558643T3 (en) * 2002-11-09 2009-09-07 Immunocore Ltd Cell receptor presentation
EP1567553A2 (en) * 2002-12-03 2005-08-31 Avidex Ltd. Complexes of receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances

Also Published As

Publication number Publication date
AU2005291039A1 (en) 2006-04-13
WO2006037960A2 (en) 2006-04-13
EP1809669A2 (en) 2007-07-25
JP2008514685A (en) 2008-05-08
CA2582963A1 (en) 2006-04-13
WO2006037960A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
MX2007003910A (en) T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.
JP2006502741A5 (en)
NZ764889A (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
HRP20220865T1 (en) T cell receptors
GT200700059A (en) EXENDINE FUSION PROTEINS
MX2012003939A (en) Drug fusions and conjugates with extended half life.
HRP20170086T1 (en) Bifunctional polypeptides
PE20120514A1 (en) FUSIONS AND CONJUGATES OF INSULINOTROPIC AGENTS OR DRUGS INCRETINE WITH DAB ANTI-SERIAL ALBUMIN ANTIBODIES
AR081042A1 (en) PEPTIDES OF THE GLUCAGON SUPERFAMILY PRESENTING ACTIVITY OF THE RECEPTOR COUPLED TO PROTEINS G
UY31123A1 (en) NATURAL FUSION PROTEINS
CY1118243T1 (en) NEW TRANSPORT CONTAINERS AND LOAD TRANSPORT CONTAINER PARTS
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
AR075504A1 (en) MOLECULES OF ANTIBODIES THAT HAVE SPECIFICITY FOR THE HUMAN OX40
IN2015DN02913A (en)
PE20171325A1 (en) POLYPEPTIDES OF THE VARIANT ACTIVIN RECEPTOR AND USE OF THEM
WO2011101681A3 (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
SI1761553T1 (en) Tumor-associated peptides that bind to mhc-molecules
WO2014052451A3 (en) Insulin analog dimers
PE20161153A1 (en) LONG-ACTING INSULIN AND USE OF THE SAME
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
DK2231860T3 (en) Polypeptide derived protein A and capable of binding PDGF
DE60319745D1 (en) MODIFIED SOLUBLE T-CELL RECEPTOR
BRPI0920573A8 (en) IMMUNOTHERAPEUTIC TCR COMPLEXES
PH12015501815B1 (en) Site-specific insulin conjugate
RU2018140056A (en) COMPOSITIONS AND METHODS USING T-CELLS WITH A CHIMERIC ALLOANTIGEN RECEPTOR

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ALSTOM RENEWABLE TECHNOLOGIES

FA Abandonment or withdrawal